CytoGenix, Inc. Announces the Appointment of a New Chief Financial Officer

CytoGenix, Inc. Announces the Appointment of a New Chief Financial Officer


NEW BRAUNFELS, Texas--(BUSINESS WIRE)--Sep 13, 2010 - CytoGenix, Inc. (Pink sheets: CYGX - News) today announced the resignation of Mr. Randy Moseley, Chief Financial Officer and Chairman of the Board from all positions within CytoGenix and the appointment of Steven M. Plumb as the new Chief Financial Officer of CytoGenix.

Steven M. Plumb, CPA, has over 25 years of experience in accounting and consulting in the technology, health care, and biotech industries. From July 2001 to the present, Mr. Plumb has served as the president of Clear Financial Solutions, Inc. a business consulting firm, which he founded in 2001, that assists public and private companies with financing, operations improvement, outsourced accounting, SEC reporting, mergers and acquisitions, and financial analysis. Mr. Plumb has served as the CFO of several public companies, including Striker Oil & Gas, Inc., Oncolin Therapeutics, Inc., Hyperdynamics Corp., Bluegate Corp., and Adventrx Pharmaceuticals, Inc. Mr. Plumb also served as the Chief Financial Officer of HoustonPharma, Inc. and 3A Pharma, LLC both of which he was a co-founder. Mr. Plumb is a Certified Public Account and a member of the American Institute of Certified Public Accounts. Mr. Plumb earned his BBA degree in accounting from the University of Texas at Austin.

Lex Cowsert, CEO of CytoGenix stated, "Steven Plumb has demonstrated uncompromising integrity, leadership, ingenuity, tenacity and flawless execution in his prior associations with some of the most respected accounting and pharmaceutical companies in the world. As our new Chief Financial Officer, Steven Plumb will bring all these qualities to CytoGenix as we continue to develop and continue to commercialize various Life Science and Energy related Bio-technologies while working to build a successful company. The vote of confidence that Steven Plumb has demonstrated by joining our executive team validates our course of action and strategic vision."

Steven Plumb, Chief Financial Officer of CytoGenix stated, "I am honored and excited about this new role at CytoGenix. It is clear that this company has shown the imagination to have made such significant break throughs with Bio-technology in several fields, with examples of proven successes and now, new challenges with great promise to contribute these discoveries for the benefit of society. I am looking forward to working with this team of key people, with such an uncompromising will to create and succeed."

CytoGenix, Inc.

CytoGenix is a Nevada corporation traded under the symbol: CYGX.PK. CytoGenix is a biotechnology company developing biotechnology derived products for vaccines and therapeutic applications for human, agricultural and veterinary markets. As such, CytoGenix has access to a broad range of biological expertise that can be leveraged to identify, evaluate, develop and commercialize biologically based technologies for energy production.

Safe Harbor Statement

The information contained in this news release, other than historical information, consists of forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. These statements may involve risks and uncertainties that could cause actual results to differ materially from those described in such statements. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct. Important factors, including general economic conditions, spending levels and other factors could cause actual results to differ materially from the Company's expectations.

 

 

Contact: CytoGenix, Inc.
Lex M. Cowsert, 830-632-5944
[email protected]

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.